Pictet Asset Management Holding SA Sells 163,821 Shares of Gilead Sciences, Inc. $GILD

Posted by George Bondi on Nov 8th, 2026

Gilead Sciences logo Pictet Asset Management Holding SA lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 6.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,348,141 shares of the biopharmaceutical company’s stock after selling 163,821 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Gilead Sciences were worth $351,407,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Client 1ST Advisory Group LLC raised its holdings in shares of Gilead Sciences by 4.0% in the third quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 69 shares during the last quarter. Bfsg LLC boosted its stake in shares of Gilead Sciences by 7.7% in the third quarter. Bfsg LLC now owns 1,003 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 72 shares during the last quarter. Grove Bank & Trust boosted its position in Gilead Sciences by 1.2% in the 3rd quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock worth $946,000 after purchasing an additional 74 shares in the last quarter. Financial Connections Group Inc. boosted its holdings in Gilead Sciences by 30.2% during the first quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 76 shares in the last quarter. Finally, Wilkerson Advisory Group LLC boosted its stake in shares of Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 78 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.4%

GILD stock opened at $166.89 on Friday. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $176.58. The firm’s 50 day moving average price is $153.04 and its 200-day moving average price is $140.94. The firm has a market cap of $207.00 billion, a PE ratio of -52.81 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company’s revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the business posted $2.47 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post -1.07 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is currently -103.80%.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 102,619 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $175.16, for a total value of $17,974,744.04. Following the transaction, the chief executive officer owned 551,683 shares of the company’s stock, valued at $96,632,794.28. This trade represents a 15.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 239,310 shares of company stock valued at $38,945,617. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on GILD shares. Needham & Company LLC set a $175.00 target price on Gilead Sciences in a research note on Friday, October 30th. Cantor Fitzgerald lifted their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. BMO Capital Markets reissued an “outperform” rating and issued a $184.00 price target on shares of Gilead Sciences in a research note on Friday, October 30th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Finally, Truist Financial raised their price objective on Gilead Sciences from $158.00 to $181.00 and gave the company a “buy” rating in a report on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $170.15.

Read Our Latest Stock Report on GILD

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead’s Livdelzi Achieves 75% ALP Normalization
Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences’ Investment Narrative?
Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.